Media ReleasesNoxopharm

View All Noxopharm News

Durable Anti-Cancer Effect Confirmed in Noxopharm’s DARRT-1 Study

  • Data on half of study patients after 6-month review to be presented to Australian cancer conference Nov 2019
  • Data suggests major anti-cancer effect of Veyonda/DARRT treatment regimen in late-stage prostate cancer
  • 80% of late-stage prostate cancer patients (reviewed to date) showing no disease progression after 6-months
  • 55% showing clinically significant reduction in pain at 6-months
  • DARRT-2 being planned for commencement in 2020

Sydney, 21 October 2019: Noxopharm (ASX: NOX) provides an update on interim data from the DARRT-1 study where Veyonda is being tested in patients with prostate cancer which is late- stage, progressive and metastatic and who have limited survival prospects.

This is ahead of a presentation by the Company of clinical data to the Clinical Oncology Society of Australia Annual Scientific Meeting, 12-14 November 2019.

For further information please download the attached PDF: Download this document